费森尤斯医疗在2025年欧洲肾脏协会大会上展示其在肾脏护理领域的新研究与创新成果-动脉网

Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025

CISION 等信源发布 2025-05-30 20:00



可切换为仅中文







Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes.

关键的摘要展示在临床护理、人工智能和液体管理方面取得了显著进展，展示了费森尤斯医疗致力于改善患者预后的承诺。

Top Abstract recognition for 'Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort,' presented in the 'Dialysis' category.

在“透析”类别中，对《美国大型血液透析队列中透析期间动脉血氧饱和度不稳定性的流行率与模式》的摘要进行了高度认可。

CONVINCE trial analysis links hemodiafiltration to slower health decline and better quality of life in key dialysis patient groups.

CONVINCE试验分析表明，血液透析滤过与关键透析患者群体健康下降较慢和生活质量提高有关。

BAD HOMBURG,

巴特洪堡，

Germany

德国

，

May 30, 2025

2025年5月30日

/PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, presents new research and innovations at the 62nd Congress of the European Renal Association (ERA),

/PRNewswire/ -- 全球领先的肾病产品和服务提供商费森尤斯医疗（FME）在第62届欧洲肾病学会（ERA）大会上展示了新的研究成果和创新技术，

June 4-7

6月4日至7日

在

Vienna, Austria

奥地利维也纳

highlighting the company's growing emphasis on data-driven insights and real-world evidence to advance patient care and improve outcomes and quality of life for people with kidney disease worldwide.

强调公司日益重视数据驱动的洞察和真实世界证据，以推进患者护理，并改善全球肾病患者的生活质量和结果。

'Our highlighted research demonstrates our continued drive to innovate in kidney care,' said

“我们重点展示的研究体现了我们在肾脏护理方面持续创新的动力，”

Frank Maddux

弗兰克·马杜克斯

, MD, Global Chief Medical Officer at Fresenius Medical Care AG. 'To further enhance our commitment to improving patient outcomes globally, our latest work focuses on Home, Critical Care and In-Center HD, and high-volume hemodiafiltration in particular. ERA is an essential platform to reinforce collaboration and drive the future of nephrology.'.

，医学博士，费森尤斯医疗保健公司全球首席医疗官。'为了进一步加强我们对改善全球患者预后的承诺，我们最新的工作重点放在家庭、重症监护和中心内的血液透析，特别是高容量的血液透析过滤。ERA是一个重要的平台，可以加强合作并推动肾病学的未来。'

Fresenius Medical Care's Global Medical Office and the company's kidney disease think tank, the

费森尤斯医疗的全球医疗办公室和该公司的肾脏疾病智库，

Renal Research Institute

肾脏研究所

(RRI), present 52 abstracts spanning critical areas of nephrology, including critical care, fluid management, hemodiafiltration (HDF), and the use of artificial intelligence (AI) in patient care.

（RRI）展示了涵盖肾脏病学关键领域的52篇摘要，包括重症监护、液体管理、血液透析过滤（HDF）以及人工智能（AI）在患者护理中的应用。

Key presentations include:

主要演讲包括：

Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort:

透析期间动脉氧饱和度不稳定的发生率和模式：美国大型血液透析队列中的观察结果：

Awarded Top Abstract for Young Authors in the 'Dialysis' category, this study, authored by RRI's Andrea Nandorine Ban, uses AI to evaluate patterns of arterial oxygen saturation during dialysis, highlighting the prevalence of intradialytic hypoxemia and its potential link to sleep apnea.

被评为“透析”类年轻作者最佳摘要，这项由RRI的Andrea Nandorine Ban撰写的研究使用人工智能评估透析期间动脉血氧饱和度的模式，强调了透析中低氧血症的普遍性及其与睡眠呼吸暂停的潜在联系。

Health Status in Different Subgroups of People Receiving Hemodiafiltration Versus Hemodialysis for Renal Replacement Therapy:

接受血液透析滤过与血液透析进行肾替代治疗的不同亚组人群的健康状况：

A subgroup analysis of the CONVINCE randomized controlled trial examines whether the slower decline in self-reported health status with hemodiafiltration (HDF) versus hemodialysis (HD) varies by age, sex, dialysis vintage, diabetes, cardiovascular disease, and vascular access type. Results highlight particular improvements in physical and cognitive function, pain interference, and social participation with HDF..

CONVINCE随机对照试验的一项亚组分析探讨了血液透析滤过（HDF）相较于血液透析（HD）在自报健康状况下降速度上的差异是否因年龄、性别、透析年限、糖尿病、心血管疾病和血管通路类型而异。结果显示，HDF在身体和认知功能、疼痛干扰以及社会参与方面有显著改善。

Impact of Fluid Overload Changes Within the First Six Months of Dialysis on Hospitalization During a Two-year Follow-up:

透析开始六个月内液体负荷变化对两年随访期间住院率的影响：

Using data collected from the Body Composition Monitor, a validated whole-body bioimpedance spectroscopy device, this study evaluates how early changes in fluid overload in hemodialysis (HD) and HDF patients are associated with hospitalization risk over a two-year period.

利用从身体成分监测仪（一种经过验证的全身生物阻抗谱设备）收集的数据，本研究评估了血液透析（HD）和HDF患者在两年内早期体液过剩的变化与住院风险之间的关联。

Delivered Hemodialysis Treatment Time and Mortality Risk: A Retrospective Analysis:

透析治疗时间与死亡风险：一项回顾性分析：

Shorter treatment times have been shown to increase mortality in hemodialysis (HD) patients. This analysis reinforces treatment time as a modifiable factor and encourages clinical teams to optimize therapy durations to improve survival outcomes for HD patients.

较短的治疗时间已被证明会增加血液透析（HD）患者的死亡率。这一分析强调了治疗时间作为一个可改变的因素，并鼓励临床团队优化治疗时长，以改善HD患者的生存结果。

Novel AI-Based Recipe Recommendation System for Dialysis Patients Using Retrieval-Augmented Generation:

基于检索增强生成的新型人工智能透析患者食谱推荐系统：

Leveraging Retrieval-Augmented Generation and OpenAI models, this innovation provides dialysis patients with personalized, scalable dietary recommendations, supporting better nutritional management.

利用检索增强生成和OpenAI模型，这项创新为透析患者提供个性化、可扩展的饮食建议，助力更好的营养管理。

In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #460 to discuss research insights, clinical collaborations, and innovations in kidney care.

除了这些展示之外，FME的领导和研究人员还将亲临460号展位，讨论研究见解、临床合作以及肾脏护理方面的创新。

To learn more about FME's presence at ERA, please click

要了解更多关于 FME 在 ERA 的信息，请点击

here

这里

。

About Fresenius Medical Care:

关于费森尤斯医疗：

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx.

费森尤斯医疗是全球领先的肾病产品和服务提供商，全球约有420万患者定期接受透析治疗。通过其3,675家透析诊所网络，费森尤斯医疗为大约这些患者提供透析治疗。

299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS)..

全球约有 299,000 名患者。费森尤斯医疗护理也是透析产品（如透析机或透析器）的领先供应商。费森尤斯医疗护理在法兰克福证券交易所（FME）和纽约证券交易所（FMS）上市。

For more information visit the company's website at

欲了解更多信息，请访问公司网站

www.freseniusmedicalcare.com

。

The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission's opinions. .

本文件中的信息按原样提供，不保证或担保这些信息适用于任何特定目的。使用者使用这些信息需自行承担风险和责任。本文件中表达的观点仅为作者的观点，绝不代表欧盟委员会的意见。

The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).

CONVINCE 研究得到了欧盟委员会研究与创新 Horizon 2020 计划的独家支持，项目编号 H2020-SC1-2016-2017，主题为 SC1-PM-10-2017：比较成人人群中现有医疗干预措施的有效性（资助编号 754803）。

Disclaimer:

免责声明：

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

本发布包含受各种风险和不确定性影响的前瞻性陈述。由于各种因素，包括但不限于业务、经济和竞争状况的变化、法律变更、监管批准、临床研究结果、汇率波动、诉讼或调查程序中的不确定性以及融资的可用性，实际结果可能与这些前瞻性陈述中描述的结果有重大差异。

These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release..

这些以及其他风险和不确定性在费森尤斯医疗护理公司向美国证券交易委员会提交的报告中有详细说明。费森尤斯医疗护理公司不承担更新本新闻稿中前瞻性声明的任何责任。

Media contact

媒体联系人

Kirsten Stratton

克里斯滕·斯特拉顿

T +1 781 929 8096

电话：+1 781 929 8096

kirsten.stratton@freseniusmedicalcare.com

Kirsten.Stratton@freseniusmedicalcare.com

Christine Peters

克里斯汀·彼得斯

T +49 160 60 66 770